Skip to main content

Table 2 In vivo efficacy of DOX-SLN and free doxycycline against B. melitensis in chronic phase

From: Doxycycline-encapsulated solid lipid nanoparticles for the enhanced antibacterial potential to treat the chronic brucellosis and preventing its relapse: in vivo study

Treatment

Chronic stage

CFUs (Log10) in spleen

Log CFUs reduction

CFUs (Log10) in liver

Log CFUs reduction

Untreated

4.96 ± 0.09

0.00

4.96 ± 0.01

0.00

Free SLN

4.94 ± 0.10

0.02

4.95 ± 0.12

0.01

DOX-SLN

3.51 ± 0.90

1.45*

3.55 ± 0.83

1.41*

Free doxycycline

3.67 ± 0.12

1.29*

3.68 ± 0.74

1.28*

  1. Comparisons were performed between all treatments and control without treatment: * P < 0.05
Back to article page

Annals of Clinical Microbiology and Antimicrobials

ISSN: 1476-0711

Contact us